orforglipron This small-molecule drug likely won't require the strict 30-minute fasting rule because the stomach does not break it down as easily
Market Segmentation Global Glucagon-Like Peptide-1 Agonists Market Size, Share & Industry Analysis, By Product Type (Short-Acting GLP-1 Agonists, Long-Acting GLP-1 Agonists), By Route of Administration (Injectable, Oral), By Application (Type 2 Diabetes, Obesity Management, Cardiovascular Disease Management), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Analysis and Forecast 20262035 Global Glucagon-Like Peptide-1 Agonists Market Size & Statistics The Market size of global glucagon-like peptide-1 agonists was estimated to be worth USD 46.18 Billion in 2025
Therefore, GLP-1 in human blood is mainly secreted through the intestine
Naltrexone-bupropion (Contrave) primarily causes nausea rather than diarrhea, affecting approximately 30% of users initially
July 12, 2025
In December 2024, Eli Lilly, the US pharmaceutical giant, announced the launch of its blockbuster drug, Tirzepatide, in India in 2025